Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Hits New 12-Month High After Analyst Upgrade

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) shares hit a new 52-week high during trading on Monday after JPMorgan Chase & Co. upgraded the stock from a neutral rating to an overweight rating. The company traded as high as $10.12 and last traded at $10.0830, with a volume of 175263 shares trading hands. The stock had previously closed at $9.67.

A number of other equities analysts have also issued reports on the company. Wall Street Zen raised Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Finally, Zacks Research cut shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Up 3.8%

The stock’s fifty day simple moving average is $8.30 and its two-hundred day simple moving average is $8.03. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.13 and a quick ratio of 0.73. The company has a market capitalization of $41.18 billion, a price-to-earnings ratio of -116.43, a PEG ratio of 5.12 and a beta of 0.69.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.